SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
Given high SARS-CoV-2 incidence, coupled with slow and inequitable vaccine roll-out in many settings, there is a need for evidence to underpin optimum vaccine deployment, aiming to maximise global population immunity. We evaluate whether a single vaccination in individuals who have already been infected with SARS-CoV-2 generates similar initial and subsequent antibody responses to two vaccinations in those without prior infection. We compared anti-spike IgG antibody responses after a single vaccination with ChAdOx1, BNT162b2, or mRNA-1273 SARS-CoV-2 vaccines in the COVID-19 Infection Survey in the UK general population. In 100,849 adults median (50 (IQR: 37–63) years) receiving at least one vaccination, 13,404 (13.3%) had serological/PCR evidence of prior infection. Prior infection significantly boosted antibody responses, producing higher peak levels and/or longer half-lives after one dose of all three vaccines than those without prior infection receiving one or two vaccinations. In those with prior infection, the median time above the positivity threshold was >1 year after the first vaccination. Single-dose vaccination targeted to those previously infected may provide at least as good protection to two-dose vaccination among those without previous infection.
Article activity feed
-
-
SciScore for 10.1101/2021.12.08.21267353: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: At the first visit, participants were asked for consent for optional follow-up visits every week for the next month, then monthly for 12 months or to April 2022.
IRB: The study received ethical approval from the South Central Berkshire B Research Ethics Committee (20/SC/0195).Sex as a biological variable not detected. Randomization COVID-19 Infection Survey (CIS) (ISRCTN21086382) randomly and continuously recruited private households to provide a representative sample across its four countries (England, Wales, Northern Ireland, Scotland). Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources SARS-CoV-2 antibody levels were tested on venous or … SciScore for 10.1101/2021.12.08.21267353: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: At the first visit, participants were asked for consent for optional follow-up visits every week for the next month, then monthly for 12 months or to April 2022.
IRB: The study received ethical approval from the South Central Berkshire B Research Ethics Committee (20/SC/0195).Sex as a biological variable not detected. Randomization COVID-19 Infection Survey (CIS) (ISRCTN21086382) randomly and continuously recruited private households to provide a representative sample across its four countries (England, Wales, Northern Ireland, Scotland). Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources SARS-CoV-2 antibody levels were tested on venous or capillary blood samples using an ELISA detecting anti-trimeric spike IgG developed by the University of Oxford28,29. anti-trimeric spike IgGsuggested: NoneSoftware and Algorithms Sentences Resources After this, it used a commercialised CE-marked version of the assay, the Thermo Fisher OmniPATH 384 Combi SARS-CoV-2 IgG ELISA (Thermo Fisher Scientific), with the same antigen and colorimetric detection. Thermo Fisher OmniPATHsuggested: NoneResults from OddPub: Thank you for sharing your code.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title ISRCTN21086382 NA NA Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
